The COVID-19 Pandemic Was Associated with a Change in Therapeutic Management and Mortality in Heart Failure Patients.

According to the Cox model, the COVID-19 pandemic was associated with a significant reduction in the utilization of Sacubitril/Valsartan (HR = 0.77, 95% CI: 0.65–0.91, model adjusted also for calendar time, given that Sacubitril/Valsartan prescriptions showed a clear trend during the study period) and implantations of CRT/ICD (HR = 0.85, 95% CI: 0.78–0.92), but it had no significant effect on the probability of receiving an MCS (HR = 1.11, 95% CI: 0.86–1.43) or undergoing a HTX (HR = 0.88, 95% CI: 0.70–1.09).

also in 19,460 other papers

In particular, a decreasing trend in HF hospitalizations during the first waves of the COVID-19 pandemic was reported, together with changes in interventional and surgical practice [ 4 , 8 ].

also in 47,180 other papers